Shengqian

Introduction to Shengqian
Hubei Shengqian Biotechnology Joint-stock Co., Ltd. is a high-tech biopharmaceutical enterprise with a completely original anti-cancer technology and a completely new business model.
Since its establishment in 2009, based on the integration of industry, academia and research of its independently developed drug-loaded vesicle tumor treatment technology, the company has built a global patent system, established production and treatment standards for drug-loaded vesicle tumor treatment technology, and innovatively created a new business model to promote the clinical translation of drug-loaded vesicle technology in the Chinese market, becoming the world's first company to successfully translate vesicle tumor treatment technology.

In February 2017, Shengqian Biotechnology was listed on the New Third Board (stock code: 870592).


Promoter of guidelines: The company has cooperated with more than 20 well-known tertiary hospitals nationwide, including the Cancer Hospital of the Chinese Academy of Medical Sciences, Wuhan Union Hospital, the Second Xiangya Hospital of Central South University, the First Affiliated Hospital of Zhengzhou University, and Tianjin Nankai Hospital; and has also cooperated with internationally renowned tumor and immunology treatment laboratories at home and abroad, such as the Tumor Immunology Laboratory of McMaster University in Canada, the Institute of Basic Medical Sciences of the Chinese Academy of Medical Sciences, and the Suzhou Institute of Systems Medicine.

The results show that the technology is safe and effective, with low toxic side effects and broad prospects for clinical promotion and application, and has attracted wide attention in China's frontline tumor treatment. The drug-loaded vesicle tumor treatment technology has a broad spectrum of indications, and the company has launched a cancer type expansion plan to expand the scope of technical indications, continue to carry out large-sample multicenter clinical trials, and optimize treatment regimens to improve evidence-based medical data.

At present, the cancer type expansion plan has attracted a large number of frontline well-known clinical experts nationwide to join, laying the foundation for improving clinical trial data and publishing related papers. In the later stage, the drug-loaded vesicle tumor treatment technology will have massive papers, massive data, massive doctors and massive hospitals, laying the cornerstone for forming expert consensus and entering China's clinical diagnosis and treatment guidelines.


Pioneer of the market: Shengqian Biotechnology has entered a period of rapid development and comprehensive market development. At present, it has started the application for clinical application pricing in 20 provinces and cities nationwide. The drug-loaded vesicle technology for treating malignant biliary obstruction has obtained price approval from Tianjin, and the drug-loaded vesicle technology for treating cancerous pleural effusion has been publicly announced by the Hubei Provincial Price Bureau.

It is expected that from July 2018, local price approvals will be obtained one after another, establishing a nationwide, networked market channel for the drug-loaded vesicle tumor treatment technology to enter the market.


Standard setter: In order to promote the industrialization of the world's first drug-loaded vesicle tumor treatment technology, Shengqian Biotechnology has established a complete preparation and quality management system and a full-process cold chain logistics transportation system, and formulated the world's * vesicle anti-cancer product production standard.

In 2017, the company's SQA 0001S-2017 "Drug-loaded Vesicles" enterprise standard was filed on the National Enterprise Standard Information Public Service Platform, becoming the world's * enterprise standard for drug-loaded vesicle tumor treatment technology. The company has also passed ISO9001 quality management system certification (certificate number: CN18/30399).

According to GMP standards, the company has established a preparation center that meets current production capacity needs and has been operating in a standardized manner for many years.

Professional managers: The company has 3 laboratories in Wuhan and Beijing. The R&D team currently has 5 professors, 8 doctors, 10 masters and 20 bachelors, and has published more than 50 articles related to internationally renowned academic vesicle anti-cancer technology in Nature Materials, Nature Communications, Cell Research, etc., with citations as high as more than 2,000 times, and has undertaken more than 20 major scientific research projects such as the "National Major Science and Technology Project for Major New Drug Creation" and the "National Key New Product Plan Project", providing deep technical support for deeply cultivating drug-loaded vesicle tumor treatment technology. In the National Key Basic Research Development Plan (also known as the "973 Plan") organized and implemented by the Ministry of Science and Technology, 3 academicians recommended and affirmed the original achievements, major innovations and breakthrough progress of the drug-loaded vesicle tumor treatment technology.

In order to promote the industrialization of drug-loaded vesicle tumor treatment technology, Shengqian Biotechnology recruits talents widely, introducing high-end professional talents from well-known domestic and foreign pharmaceutical companies such as Roche Pharmaceuticals and Buchang Group, and has set up core business departments such as the R&D Department, Quality Department, Medical Department and Access Department, which are respectively responsible for the company's product research and development, production quality control, product positioning and market promotion, making full preparations for the company to fully enter the market.

Through cooperation with *** hospitals and improving the expert system, the Shengqian management team has built a product chain for drug-loaded vesicle tumor treatment technology, established a professional and standardized product diagnosis and treatment system and enterprise management system, innovated the business model, accelerated the clinical translation of the original anti-cancer technology of drug-loaded vesicle tumor treatment, and provided a new cancer solution for cancer patients in China.

Shengqian Biotechnology will adhere to the original intention of "doing one thing beneficial to society in a lifetime", always focusing on the research and development and clinical translation of drug-loaded vesicle tumor treatment technology, striving to become the * in China's original anti-cancer field and benefit tumor patients.